| Date | Title | Description |
| 17.03.2025 | MicroTransponder Secures $65 Million to Revolutionize Stroke Recovery | In the heart of Austin, Texas, a medical device company is making waves. MicroTransponder has just raised $65 million in Series F funding. This investment is a significant step forward in the company’s mission to transform stroke recovery. ... |
| 16.03.2025 | MicroTransponder: $65 Million (Series F) Raised For Enhancing Vivistim Adoption For Chronic Stroke Recovery | MicroTransponder – which is one of the fastest-growing stroke companies – announced it is transforming the stroke continuum of care with its FDA-approved Vivistim Paired VNS System. The company also announced it has raised $75 million led b... |
| 13.03.2025 | MicroTransponder Raises $65M in Series F Funding | MicroTransponder, an Austin, TX-based medical device company, raised $65M in Series F funding.
The round was led by US Venture Partners (USVP) and the syndicate of current investors, Osage University Partners, Action Potential Venture Capit... |
| 13.02.2025 | Helicore Biopharma: $65 Million (Series A) Raised For Glucose-Dependent Insulinotropic Peptide Platform | Helicore Biopharma, a biopharmaceutical company focused on discovering and developing first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists for obesity and related conditions, announced its emergence from stealth mode wi... |
| 09.01.2025 | FIRE1: $120 Million Funding Raised For Transforming Heart Failure Care | FIRE1 – a leading connected medical device solutions company – announced the completion of a $120 million financing round to accelerate the company’s mission to transform the lives of millions of people living with heart failure. The fundin... |
| 08.01.2025 | FIRE1 Secures $120M for Heart Failure Management Platform | What You Should Know:
– FIRE1, a connected medical device company, announced it has secured $120M in funding to advance its mission to transform the lives of millions of people living with heart failure. The round was led by Polaris Partner... |
| 07.01.2025 | Jeito Capital's Bold Moves in Biopharma: A Strategic Investment Landscape | In the world of biopharma, where innovation is the lifeblood, Jeito Capital is making waves. This Paris-based private equity fund is not just dipping its toes; it’s diving deep into the ocean of clinical-stage biotech. With a recent investm... |
| 07.01.2025 | FIRE1 heats up with $120M for its heart failure monitor implant | Things are heating up for FIRE1, which posted a $120 million funding round to support its implant for tracking the hidden signs of heart failure.
The Dublin-based company also announced that the FDA has handed down a breakthrough designatio... |
| 07.01.2025 | Aviceda raises $207M series C to take geographic atrophy drug through phase 3 | Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 readout this year for its lead eye disease drug.
The round was co-led by the healthcare funds Omega Funds and TCGX, wi... |
| 07.01.2025 | FIRE1 Secures $120M Financing | FIRE1, a Dublin, Ireland-based connected medical device solutions company, raised $120M in funding.
The round was led by Polaris Partners and Elevage Medical Technologies, joined by new investors Sands Capital and Longitude Capital, and exi... |
| 07.01.2025 | French PE fund Jeito Capital invests in global biopharma growth with Aviceda and XyloCor Therapeutics | Paris-based Jeito Capital, a PE fund focused on biopharma innovation, has furthered its position as a player in global healthcare investment with two major contributions to clinical-stage biotech companies Aviceda Therapeutics and XyloCor T... |
| 20.11.2024 | Alentis Therapeutics: $181.4 Million (Series D) Raised For Advancing Clinical Development Of Anti-Claudin-1 ADCs | Alentis Therapeutics – a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis – announced that it has raised $181.4 million in Series D financing, supported by a syndicate of t... |
| 13.11.2024 | Alentis Therapeutics Secures $181.4 Million to Pioneer Cancer Treatments | In a bold move to reshape cancer treatment, Alentis Therapeutics has successfully raised $181.4 million in an oversubscribed Series D funding round. This infusion of capital, led by OrbiMed and co-led by Novo Holdings and Jeito Capital, sig... |
| 13.11.2024 | Alentis Therapeutics: $181.4 Million (Series D) Raised To Develop Treatments For Claudin-1 Tumors | Alentis Therapeutics – a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis – announced that it has raised $181.4 million in Series D funding, supported by a syndicate of top... |
| 12.11.2024 | Alentis Therapeutics raises $181.4 million in oversubscribed series D round | Normal 0 false false false EN-GB X-NONE AR-SA
Besides OrbiMed, Novo Holdings and Jeito Capital, Alentis Therapeutics’ series D round saw the participation of new investors Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Hea... |
| 23.10.2024 | Alpha-9 Oncology Raises $175M in Series C Financing | Alpha-9 Oncology Inc., a Boston, MA- and Vancouver, Canada-based clinical stage company developing radiopharmaceuticals to meaningfully improve the treatment of people living with cancer, raised $175m in Series C financing.
The round was le... |
| 30.07.2024 | Kestra Medical and T. Rowe Price: Pioneering Innovations in Healthcare and Sustainable Finance | In the ever-evolving landscape of healthcare and finance, two companies are making waves. Kestra Medical Technologies is redefining cardiac care with its innovative wearable devices. Meanwhile, T. Rowe Price is spearheading sustainable inve... |
| 29.07.2024 | Kestra Medical: Wearable Cardioverter Defibrillator Company Closes $196 Million In Funding | Kestra Medical Technologies (a privately held wearable medical device and digital healthcare company) announced an oversubscribed $196 million funding round to support the expansion of their commercial organization and advance its goals of ... |
| 06.07.2024 | Endogenex: $88 Million Raised To Improve Outcomes In Individuals With Type 2 Diabetes | Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes, announced it closed an oversubscribed Series C financing totaling $88 million.
The new funding round will be used to com... |
| 14.05.2024 | Cohere Health Launches Early Trend Signal Intelligence to Predict Utilization Trends Earlier than Claims-based Methods | Leverages intelligent prior authorization to inform policy and financial strategies up to three months earlier
BOSTON, May 14, 2024 /PRNewswire/ -- Cohere Health®, a recognized leader in clinical intelligence and prior authorization automat... |
| 23.04.2024 | Cohere Health and Humana Expand Prior Authorization Partnership, Adding Diagnostic Imaging and Sleep Services | New solutions elevate and expedite patient care with upstream moments of influence
BOSTON and LOUISVILLE, Ky., April 23, 2024 /PRNewswire/ -- Cohere Health, a recognized leader in clinical intelligence and prior authorization automation, an... |
| 12.03.2024 | Venus Concept Launches “NEXThetics” Program | New Venus AI Event Series Focused on Enhancing Customer Education and Training
TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic ... |
| 22.11.2022 | Opna Bio Launches with $38 Million Series A Financing | |
| 06.04.2022 | IntelyCare Secures $115M for Intelligent Nurse Staffing Platform at $1.1B Valuation | What You Should Know:
– IntelyCare, a leading intelligent workforce management solution for post-acute facilities raises $115M to solve the nationwide nurse shortage.
– IntelyCare plans to build on this momentum by using the new funding to ... |
| 07.01.2021 | Cortica Raises $60M to Expand Comprehensive Autism Care Model Nationwide | What You Should Know:
– Cortica, Inc. (“Cortica”), a San Diego, CA-based tech-enabled clinical services for autism and other neurodevelopmental conditions, announced it has raised $60 million in financing to further its mission to transform... |
| 23.09.2020 | Healthcare VC Firm Longitude Capital Closes $585M Fund | What You Should Know:
– Healthcare venture capital firm Longitude Capital announces the close of its $585M Longitude Venture Partners IV, L.P. (“LVP4”) fund to invest in transformative healthcare companies.
– LVP4 will invest opportunistica... |
| 25.06.2020 | Polares Medical Closes a $40M Financing to Complete Pilot Clinical Studies | |
| 25.06.2020 | Polares Medical Closes a $40M Financing to Complete Pilot Clinical Studies | Polares Medical SA, a clinical stage medical technology company based in Lausanne announced today the closing of a $40 million financing led by Longitude Capital (Menlo Park) with the participation of Decheng Capital (Menlo Park / Shanghai)... |
| 23.06.2020 | Somatus Lands $64M to Expand Value-Based Kidney Care Model | What You Should Know:
– Somatus raises $64M in Series C funding led by Longitudinal Capital to fuel the expansion of its value-based kidney care model.
– Somatus will use the funding to continue to scale its model nationally and invest in t... |
| 17.02.2017 | Longitude Capital Promotes Josh Richardson to Managing Director | Longitude Capital, a private investment firm focused on venture growth investments in biotechnology and medical technology, promoted Josh Richardson, M.D. to Managing Director.
Dr. Richardson focuses on investments in biotechnology companie... |
| 17.02.2017 | Term Sheet — Friday, February 17 | IT’s TIME TO TAKE AI SERIOUSLY
The following is from the latest print edition of Fortune, where I write a regular column about technology and startups called “💥Boom with a View💥.”
Paid Content You can't secure what you can't see From ExtraH... |
| 16.02.2017 | Longitude Capital Promotes Josh Richardson, M.D., To Managing Director | Longitude Capital, a private investment firm focused on venture growth investments in biotechnology and medical technology, today announced the promotion of Josh Richardson, M.D. to Managing Director.
Dr. Richardson focuses on investments i... |
| 16.02.2017 | Longitude Capital Promotes Josh Richardson, M.D., To Managing Director | Longitude Capital, a private investment firm focused on venture growth investments in biotechnology and medical technology, today announced the promotion of Josh Richardson, M.D. to Managing Director.
Dr. Richardson focuses on investments i... |
| 27.07.2016 | Tricida raises $55M to prep trials, commercial path for kidney drug | Tricida declined to comment about the funding beyond its news release, which said that the capital will be used to finance late-stage clinical trials of its lead drug candidate, TRC101.
Tricida is currently evaluating its compound in 100 pa... |
| 25.07.2016 | Longitude Capital Leads $55M Series C for Tricida | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc., a privately-held, clinical stage, biopharmaceutical company focused on the discovery and development of first-in-class chronic therapies for patients with chronic kidney disease (... |
| 07.06.2016 | Longitude Capital Closes $525 Million Fund | Longitude Capital, a private investment firm focused on venture growth investments in biotechnology and medical technology, today announced the closing of Longitude Venture Partners III, L.P. with $525 million in partner commitments, exceed... |
| 07.06.2016 | Longitude Capital raises $525M for third fund spanning early to late stage medtech investments | The investment firm expects to invest an average of $15 million to 25 million per investment in approximately 25 companies. It raised $385 million for its second fund in 2012.
Galletti highlighted some of the technologies in which it has de... |
| 07.06.2016 | Biotech & Medtech Venture Capital Firm Longitude Capital closes Fund, at $525M | Longitude Capital, an investment firm focused on venture growth investments in biotechnology and medical technology, closed its third fund, at $525m in partner commitments.
Longitude Venture Partners III, L.P. (“LVP3”), which exceeded the i... |
| 12.05.2016 | Longitude Capital to Raise $525M Venture Capital Fund | Longitude Capital, a private equity investment firm that focuses on venture growth investments in drug development and medical technology, is to raise a new fund.
According to a regulatory document filed with the SEC, the firm is seeking $5... |
| 02.12.2015 | Daily funding roundup - December 2, 2015 | ORIC Pharmaceuticals bagged $53M; Bluecore raised $21M; Osaro announced $3.3M funding
Technology innovators Realsafe Technologies have secured £1 million (approximately $1.5 million) of investment to scale their business, bringing with it n... |
| 24.11.2015 | Daily funding roundup - November 24, 2015 | Placester secured $27M; Shiftgig raised $22M; Fortscale announced $16M funding
Lenda, a first platform that allows homeowners to refinance their mortgage completely online, today announced the close of $2 million in seed funding led by Lake... |
| 22.05.2015 | Longitude Capital Promotes Sandip K. Agarwala to Managing Director | Longitude Capital, a private investment firm that focuses on venture growth investments in drug development and medical technology, promoted Sandip K. Agarwala to Managing Director.
Mr. Agarwala joined Longitude in 2013 and focuses on struc... |
| 26.08.2014 | California Cryobank Acquired by Equity Investors | California Cryobank (CCB), a global provider of reproductive tissue donor services and storage and stem cell banking, has been acquired by equity investors Longitude Venture Partners II, L.P. and NovaQuest Pharma Opportunities Fund III, L.P... |
| 15.04.2014 | Rapid Micro Biosystems Closes Additional Funding | Rapid Micro Biosystems, a Bedford, MA-based provider of automated, non-destructive, rapid microbial detection for quality control testing of pharmaceutical and personal care products, closed on additional funding of undisclosed amount.
Back... |
| 07.01.2014 | Incubator with six venture-backed spinouts seeks 2014 exit, unveils new sepsis spinout | The six venture-backed spinouts include:
Baronova, a startup trying for weight loss devices that are both non-surgical and non-pharma. The company closed a $27.3 million Series C round in February 2013, which was led by Boston Scientific (B... |
| 29.11.2013 | The sharks of healthcare: 5 VCs that should be on ABC | Let’s start with the investors. Here are my picks for the panel. I have heard most of these people speak at events or judge pitch contests or read their blogs. It’s a good mix of venture capitalists from across the country.
Noubar Afeyan – ... |
| 29.06.2013 | Rapid Micro Biosystems Raises $32.6M in Series B Financing | Rapid Micro Biosystems, a Bedford, MA-based provider of microbial detection for quality control testing within the pharmaceutical and personal care products market segments, raised $32.6m in Series B financing.
The round was led by Longitud... |
| 25.04.2013 | Esperion Therapeutics Raises $33M to Further Clinical Trials | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
The Ann Arbor-based biotech company Esperion Therapeutics announced today that it has completed a $33 million round of preferred stock financing. Longitude Capital led the rou... |
| 25.04.2013 | Esperion Therapeutics Completes $33M Financing | Esperion Therapeutics, Inc., a Plymouth, MI-based clinical stage biopharmaceutical company, completed a $33m financing.
The round was led by new investor Longitude Capital, with participation from existing investors Aisling Capital, Alta Pa... |
| 21.03.2013 | Pediatric drug developer with treatment for infantile jaundice could reduce readmissions | InfaCare’s drug Stanate was licensed from Rockefeller University. A heme oxygenase inhibitor, Stanate prevents the breakdown of heme in the body. It is designed to significantly reduce the body’s production of bilirubin over a six- to eight... |
| 10.10.2012 | Longitude Capital Closes Second Fund at $385M | Investment firm Longitude Capital has closed its second fund, at $385m.
Longitude Venture Partners II, L.P., which had a target of $325m, will focus on investments in drug development and medical technology.
Led by co-founders and Managing ... |
| 10.10.2012 | Life science investor Longitude Capital will use its $325M fund in later-stage deals | Longitude has invested in companies from its back yard in Menlo Park but also from Boston to Newport, Kentucky, to Pittsburgh to Dublin, Ireland. And they range from heart diagnostics companies to spinal medical device business to pediatric... |
| 10.09.2012 | Longitude Venture Partners goes after a $375M second fund for life science investments | Attractive deals for Longitude are with companies developing clinically and cost-effective treatments for unmet medical needs, and platform technologies that facilitate novel product development, the firm says on its website. It gives prefe... |
| 08.02.2012 | Longitude Capital Expands Investment Team With Senior Hire | - Dr. Gregory Grunberg Joins as Managing Director -
MENLO PARK, Calif. and GREENWICH, Conn., Feb. 8, 2012 /PRNewswire/ -- Longitude Capital, a life sciences venture capital firm, today announced that Gregory Grunberg, M.D., has joined the f... |
| 10.01.2011 | Civitas Therapeutics Raises $20M in Series A Financing | Civitas Therapeutics, Inc., a Chelsea, MA-based biopharmaceutical company focused on developing innovative pulmonary delivery therapies, has raised $20m in Series A financing.
The round was co-led by founding investor, Longitude Capital, as... |
| 08.01.2009 | Aptus takes $30M to repair aneurysms | Aptus Endosystems, a biotech firm working on a device to fix abdominal aneurysms, just brought in $30 million in third-round funding to finish off clinical trials of its Abdominal Aortic Aneurysm Repair System, reports VentureWire. Heron Ca... |
| - | Tricida raises $55M to prep trials, commercial path for kidney drug | Patients who have chronic kidney disease face permanent kidney damage and the prospect of end-stage renal failure. Clinical-stage drug developer Tricida is trying to bring patients who suffer from this condition a new treatment and it now h... |
| - | Life science investor Longitude Capital will use its $325M fund in later-stage deals | Longitude Capital will use its new $385 million fund to invest in later-stage life science companies.
Longitude made the announcement Wednesday, but word had leaked out about the size of the fund (oversubscribed) in the past several weeks. ... |
| - | Longitude Capital raises $525M for third fund spanning early to late stage medtech investments | Longitude Capital, a life science investment firm targeting mostly mid to late stage companies with about one quarter for early stage businesses, has made its first close for Longitude Venture Partners III, raising a total of $525 million, ... |
| - | The sharks of healthcare: 5 VCs that should be on ABC | I am late to the party but it’s official. I love Shark Tank. My favorite pitch so far has been the farmer with the tree guard for young trees. Johnny George’s Tree T Pee is a real product: it serves a purpose and it saves money for business... |
| - | Incubator with six venture-backed spinouts seeks 2014 exit, unveils new sepsis spinout | TheraNova is a San Francisco-based sandbox incubator and capital technology developer for medical devices. With one exception, all the ideas for technology are internally generated, CEO Dr. Daniel Burnett said. That’s led to all its medical... |
| - | Longitude Venture Partners goes after a $375M second fund for life science investments | Here’s another name to add to the list of life science-focused venture firms raising or closing funds over $100 million this year: Longitude Venture Partners.
The VC firm that specializes in medical device, biotechnology, diagnostics and R&... |
| - | Pediatric drug developer with treatment for infantile jaundice could reduce readmissions | A pediatric drug developer has raised $3.55 million — the first tranche of a $21.5 million series C Round to advance its drug to treat infantile jaundice or hyperbilirubinemia through a phase 2 clinical trial. It initiated recruitment for t... |